Annals of Oncology 1996: Vol 7 Index

27 Pages·1996·6.2 MB·English

Annals of Oncology 7: 1087-1103, 1996.
Index of subjects Volume 7 (1996)
A advanced colorectal carcinoma
a-interferon factors influencing response rates (Arena) 901
as a treatment for patients with metastatic colorectal carcinoma 575 treatment with oxaliplatin (Short report) 95
as a treatment for patiwiethn mettstsati c carcinoiadn d malignant endocrine advanced multiple myeloma
pancreatic tumours (Short report) 208 use of oral idarubicin and prednisone (Letter to the editor) 537
as a treatment for patients with neuroendocrine gastrointestinal tumours advanced non-small-cell lung cancer
(Review) 459 use of radiotherapy preceded by high-dose chemotherapy versus high-
in combination therapy with 5-fluorouracil (Short report) 208, 575 dose radiotherapy 139
acute aortic thrombosis advanced ovarian cancer
in patients with small-cell lung carcinoma (Letter to the editor) 321 single agent activity of oxaliplatin 1065
acute lymphoblastic leukemia advanced pancreatic adenocarcinoma
meta-analysis and prospective meta analysis in clinical research (Arena) treatment with 5-fluorouracil, leucovorin and cisplatin 173
1009 advanced salivary gland carcinoma
monitoring L-asparagine depletion in plasma and cerebro-spinal fluid 725 treatment with chemotherapy (Short report) 640
secondary malignancies (Letter to the editor) 322 treatment according to CAP regimen (Short report) 640
succesful treatment (Letter to the editor) 322 advanced squamous cell carcinoma of head and neck
acute myelogenous leukemia phase II trial (Letter to the editor) 539
probability of long-term disease-free survival 933 treatment with 13-cis retinoic acid plus interferon-a (Letter to the editor)
adenocarcinoma 539
oft he esophagus or esophago-gastric junction area (Short report) 533 advanced stages
adenoid cystic carcinoma of Hodgkin's disease (Review) S4: 99
in head and neck (Short report) 867 aetiology
treatment with mitoxantrone (Short report) 867 in Hodgkin’s disease (Review) S4: 5
ADEPT AIDS
used in cancer drug therapy (Special article) 445 related to non-Hodgkin's lymphoma 1029
adjuvant chemo-tamoxifen therapy akathisia
as a treatment for patients with early breast cancer 239 associated with prochlorperazine as an antiemetic (Editorial) 103
risk of new primaries 239 allogeneic blood progenitor cells
adjuvant chemotherapy transplantation of (Review) S2: 41
as a treatment for patients with breast cancer (Short report) 745 allogeneic bone marrow transplantation
as a treatment for patiewintht esar ly breast cancer 239 schedules in high-dose chemotherapy 83
long-term results in stage I and II] Hodgkin’s disease 145 allogeneic transplantation
risk of new primaries 239 of cord blood (Review) S2: 47
adjuvant surgery of Ph1-negative blood progenitor cells inc hronic myelogenous leukaemia
as a treatment for patients with small-cell lung cancer 303 (Review) S2: 19
adjuvant systemic treatment American perspective
in breast cancer (Editorial) 221 on clinical benefit (Editorial) 335
adjuvant tamoxifen AML
as a treatment for patients with early breast cancer 239 cytokine production 397
risk of new primaries 239 treatment with interleukin 10 397
adjuvant therapy anaplastic
as a treatment for patients with breast cancer 245 carcinoma of the thyroid (Clinical case) 739
as a treatment for patients with colon cancer (Short report) 412 angiogenesis
effect of occurences in second malignancies 245 bFGF and VEGF 843
multifocal leukoencephalopathy (Short report) 412 angiogenesis inhibitors
adjuvant treatment clinical studies (Editorial) 441
in node-annd eestrgogena retcepitorv-negeati ve breast cancer 481 phase I study 491
adoptive cellular therapy tecogalan sodium 491
as a treatment for patients with metastatic renal cell cancer (Review) 887 animal study
advanced breast cancer stem cells in mice (Review) S2: 15
mobilisation kinetics of primitive haemopoietic cells following G-CSF antibodies
1051 as anticancer agents (Special article) 445
treatment with doxorubicin and paclitaxel 687 anticancer chemotherapy
treatment with intravenous infusion of 5-fluorouraci8l0 7 as a treatment for patients with breast cancer 165
1088
multicentre phase II study 165 survival improvement in patients 593
antineoplastic agents biochemical modulation
use in the therapy of HIV-related non-Hodgkin’s lymphoma 1029 as a treatment for patients with advanced colorectal cancer 581
antiprogestins of 5-FU with leucovorin 581
in the human breast cell line T-47D 391 biochemotherapy
induction of TGF-beta 391 treatment of patients with metastatic melanoma 827
antiretroviral therapy biological markers
use in HIV-related non-Hodgkin’s lymphoma 1029 diagnostic and prognostic value 607
antithrombin III in neuroblastoma 607
interaction between HRT and tamoxifen 671 biology
application schedules report on the workshop of the Third International Symposium on
in patients with bone marrow transplantation 83 Hodgkin’s Lymphoma in Cologne 1995 (Symposium article) S4: 45
aPTT bioreductives
pentosan 939 as a new approach in cancer chemotherapy (Special article) 445
aromatase inhibitors biotherapy
as a treatment of patients with advanced breast cancer 471 in combination with chemotherapy 827
as a treatment of patients with breast cancer (Short report) 99 treatment of patients with metastatic melanoma 827
new generation of (Editorial) 433 bispecific antibodies
arthralgia treatment of Hodgkin’s disease (Review) S4: 143
in a patient with metastatic carcinoma of the breast (Letter to the editor) bladder cancer
756 treatment with combination chemotherapy (Short report) 751
attitudes bone marrow
toward euthanasia 907 analysis of prognostic factors associated with hematopoietic recovery 719
autograft autotransplant of progenitor cells 719
hematopoietic recovery 719 study of haemopoietic stem cells (Review) S2: 5
autologous blood stem cell transplantation bone marrow stromal cultures
for patients with chronic lymphocytic leukemia 373 as a therapy for patients with advanced breast cancer 1051
long-term survival 373 bone marrow transplantation
autologous bone marrow transplantation and high-dose chemotherapy 151
in patients with acute myeloid leukemia 933 as a treatment in patients with Hodgkin’s disease 151
in patients with breast cancer (Review) S2: 31 use in therapy of low-grade non-Hodgkin’s lymphomas (Review) S6: 13
autologous transplantation bone metastases
haemopoietic stem cells (Review) S2: 5 treatment with prednisone (Letter to the editor) 640
of Ph1-negative blood progenitor cells (Review) S2: 19 bone mineral density
in patients with chronic myelogenous leukaemia (Review) S2: 19 effect of tamoxifen and hormone replacement therapy 671
bone sarcomas
B treatment with neoadjuvant chemotherapy (Short report) 864
B-cell lymphoma breast cancer
new classification (Review) S6: 3 antiprogestins 391
classification and therapeutic implications (Review) S6: 35 carcinomatous meningitis (Review) 773
B-CLL detection of 619
evolution into chronic lymphocytic leukaemia (Clinical case) 953 dose-intensive chemotherapy for 35
bax effects of adjuvant systemic treatment (Editorial) 221
in relation to Bcl-2 in breast cancer (Rapid publication) 129 effects of fadrozole versus tamoxifen 471
bel-1 effects of prednisone combined with CMF 245
involvement of the CCND1 gene 251 efficacy and safety of docetaxel as first-line treatment 165
bel-2 expression of Bax in relation to Bcl-2 (Rapid publication) 129
clinical significance for patients with diffuse large B-cell lymphomas 1023 hormonal replacement therapy 655
expression of Bax in breast cancer (Rapid publication) 129 induction of TGF-beta 391
bcl-2 rearrangement locally advanced 165
detection of cells (Rapid publication) 793 metastatic 165, 465, 487
in patients with non-Hodgkin’s lymphoma (Rapid publication) 793 node-negative 481
Ber-H2/saporin phase II trial (Short report) 857
for clinical use in Hodgkin’s disease (Review) S4: 135 pretreated 55S
bilharziasis psychological distress (Letter to the editor) 977
treatment with combination therapy (Short report) 751 role of maspin gene 619
biliary cancer treatment with adjuvant chemotherapy 239, 745 (Short report)
and the quality of life 593 treatment with adjuvant therapy 245, 695, 977 (Letter to the editor)
treatment with CMF-inf (Short report) 409 cardiotoxicity
treatment with 8-chloroadenosine 3’ ,5’ monophosphate 291 of 5-fluorouracil 731
treatment with paclitaxel and vinorelbine (Short report) 857 of combined doxorubicin and paclitaxel in advanced breast cancer 687
treatment with tamoxifen 239 CARES-SF
use of aromatase inhibitors in treatment of patients with (Short report) 99 and the quality of life 381
breast neoplasms validity and reliability 381
dose intensification (Review) $2: 31 causes of death
peripheral blood progenitor cells (Review) S2: 11 of patients with Hodgkin's disease (Review) S4: 115
CCND1
Cc in hairy cell leukemia 251
CA 125 cDNA libraries
progression of ovarian carcinoma 361 its role for analysis of Hodgkin's disease (Review) S4: 35
cancer CD30
CARES-SF 381 ligand interaction in Hodgkin's lymphoma (Symposium article) S4: 45
chemotherapy (Special article) 445 CD34+ blood cells
elderly patients 677 allogeneic transplantation (Review) S2: 41
euthanasia 907 transduction of (Review) $2: 53
incidence and mortality 497 CD34+ cells
palliative and supportive care (Arena) 135 loss from (Review) S2: 47
patient perceptions of the effects of chemotherapy 189 positive selection of ex vivo expansion of (Review) $2: 11
quality of life 381 cell culture model
research (Editorial) 439 influence of 5-FU 731
treatment (Editorial) 657 cell cycle regulation
treatment with pentosan 939 fundamental research on (Commentary) 343
use of hypnotics (Short report) 855 cell transplantation
cancer drug development as a treatment for patients with inoperable relapse of nuchal liposarcoma
phase I trials (Commentary) 567 (Letter to the editor) 871
cancer pain cervical cancer
use of methadone 613 treatment with concurrent chemo- and radiotherapy 511
cancer therapy CGS 16949A
use of the nuclear matrix (Review) 659 treatment in women with advanced breast cancer 471
cancer vaccines versus tamoxifen 471
immune monitoring of (Commentary) 667 challenges
peptide-based (Review) 339 for the future in ovarian cancer research 9
recognition of tumour-associated antigens (Review) 339 chemoradiotherapy
CAP regimen treatment for patients with small-cell lung cancer 303
as a treatment for patients with advanced salivary gland carcinoma (Short chemoprevention
report) 640 instead of cancer chemotherapy (Special article) 445
carboplatin chemotherapy
as a treatment for patients with locally advanced carcinoma of the cervix alone in treatment of early stage Hodgkin's disease (Review) S4: 85
511 and G-CSF for patients with advanced breast cancer 1051
as a treatment for patients with good-risk metastatic non-seminomatous as a treatment
germ cell tumours 1015 for elderly patients (Short report) 966
as a treatment for patients with small-cell lung cancer 365 for patients with
comparison with cisplatin 365 advanced bilharzial bladder carcinoma (Short report) 75!
in combination chemotherapy of non-semingoermm acetll otuumosur s advanced breast cancer 807
(Editorial) 989 advanced colorectal cancer (Arena) 901, (Short report) 961
in combination with teniposide and vincristine 365 advanced endometrial cancer (Short report) 861
carcinoid advanced pancreatic cancer 593
treatment with a combination of interferon-a-2a and 5-fluorouracil (Short advanced salivary gland carcinoma (Short report) 640
report) 208 advanced testicular chorioca(Lrettceri ton tohe medaito r) 536
carcinoids biliary cancer 593, (Letter to the editor) 644
as part of the neuroendocrine gastrointestinal tumours (Review) 453 bone sarcomas (Short report) 864
carcinomatous meningitis breast cancer 35, S2: 31 (Review)
in solid tumours (Review) 773 carcinoma of the thyroid (Clinical case) 739
cardiac sequelae cervical cancer 511
after treatment for Hodgkin's disease 257 chronic myelogenous leukaemia (Review) S2: 19
increased risks in females 257 esophageal carcinoma 353
5-FU-refractory pancreas cancer (Rapid publication) 347 advanced pancreatic adenocarcinoma 173
head and neck cancer (Review) 15 good-risk metastatic non-seminomatous germ cell tumours 1015
Hodgkin’s disease 257, (Special article) 555, (Review) S4: 109, non-small cell lung cancer and malignant melanoma (Short report)
(Clinical case) 1071 1080
metastatic melanoma 827 ovarian cancer 65, 1077 (Short report)
non-Hodgkin’s lymphomas (Short report) 966, S6: 13 (Review) small-cell lung cancer 365, 747 (Short report)
non-seminomatous germ cell tumours 1015, (Editorial) 989 compared to carboplatin 365
non-small-lung cancer 311, (Short report) 414, 517, (Short report) in combination with teniposide and vincristine 365
637, 821 inducement of delayed emesis 945
ovarian carcinoma 65, 705 phase III study in non-small-cell lung cancer 517
solid tumours (Review) S2: 23 cisplatin resistance
testicular cancer 31 in testicular cancer 31
combined with radiotherapy 919 cladribine
CPT-11 dosage 837 treatment for patients with non-Hodgkin’s lymphoma (Rapid publication)
for bulky or advanced Hodgkin’s disease (Review) S4: 105 793
haemopoietic stem cells (Review) S2: 5 classification systems
historical control studies 355 of mantle-cell lymphoma (Review) S6: 35
improvement of quality of life 593 clinical
in advanced Hodgkin’s disease (Review) S4: 95 research of ovarian cancer 9
in combination with biotherapy 827 studies with angiogenesis (Editorial) 441
low-dose continous intravenous infusion of 5-fluorouracil 807 trials in Hodgkin’s disease (Review) S4: 109, 127
low-dose cisplatin- or non-cisplatin 505 clinical benefit
neoadjuvant (Short report) 864, (Letter to the editor) 871 an American perspective (Editorial) 335
occurrence of cardiopulmonary sequelae 257 an European perspective (Editorial) 333
optimum anti-emetic therapy 277 for patients with pancreatic cancer (Rapid publication) 347
patient perceptions of side effects 189 phase II trial of gemcitabine (Rapid publication) 347
peripheral blood progenitor cell transplantation (Introduction) $2: 1 Clinical cases
phase I study (Short report) 311, 314 anaplastic
phase II study (Rapid publication) 347, (Short report) 637, (Short report) carcinoma of the thyroid 739
861 B-CLL
phase III randomised trial 821 evolution into chronic lymphocytic leukaemia 953
prolongment of survival 593 chemotherapy
pulmonary toxicity (Short report) 973 as a treatment for patients with carcinoma of the thyroid 739
purging of peripheral blood progenitor cells (Review) S2: 11 as a treatment for patients with Hodgkin’s disease 1071
randomized trials 355 clonality
childhood in B-cell lymphoma 953
present and future strategies of Hodgkin’s lymphoma’s treatment (Review) corticosteroids
$4: 73 in granulosa cell tumour of the ovary 521
cholesterol follicular lymphoma
interaction between HRT and tamoxifen 671 histological transformation 849
choriocarcinoma granulosa cell tumour
diagnosis of residual disease (Short report) 416 of the ovary 521
diagnosis of tumour emboli (Short report) 416 Hodgkin’s disease
positron emission tomography (Short report) 416 complications by second cancers 405
chromograninA meningeal localization in a patient 1071
in neuroendocrine gastrointestinal tumours (Review) 454 immunogenotype
chronic lymphocytic leukemia (CLL) in lymphocytic leukemia 953
long-term survival 373 immunophenotype
purine analogs (Review) S6: 27 in lymphocytic leukemia 953
treatment with 2-CdA-therapy 373 leukaemia
chronic myelogenous leukaemia complicating Hodgkin’s disease 405
mobilization/transplantation of Ph1-negative blood progenitor cells (Review) lung cancer
$2: 19 role of surgery in small-cell 303
CHVmP lymphoma
as a treatment for patients with non-Hodgkin’s lymphomas 925 clonal analysis 953
cisplatin evolution into lymphocytic leukemia 953
as a treatment for patients with meningeal lymphoma
advanced endometrial cancer (Short report) 861 in patients with Hodgkin’s disease 1071
1091
prognosis treatment with 5-fluorouracil plus oral leucovorin 581, (Short report) 961
for patients with follicular lymphoma 849 treatment with tomudex 179, (Short report) 961
radiation combined chemotherapy-radiotherapy
therapy for patients with anaplastic carcinoma of the thyroid 739 as a treatment for patients with localized low-grade lymphoma 157
radiotherapy combined modality therapy
as a treatment for patients with Hodgkin's disease 1071 as a treatment for patients with bulky or advanced Hodgkin's disease
second cancers (Review) S4: 105
in Hodgkin's disease 405 as a treatment for patients with Hodgkin's disease (Special article) 555
leukemia 405 as a treatment for patients with non-Hodgkin's disease 925
small-ceil lung cancer as a treatment for patients with stage I, IIT MALT lymphoma and mantle
the role of surgery 303 cell lymphoma (Letter to the editor) 211
thyroid cancer complete remission
anaplastic 739 after 2-CdA therapy 373
transformation in patients with CLL 373
of indolent lymphoma 849 continuous infusion
treatment for patients with advanced colorectal cancer 581
of patients with foilicular lymphoma 849 of 5-HU plus leucovorin 581
of patients with granulosa cell tumour of the ovary 521 cord blood
tumour lysis syndrome as an alternative source of haemopoietic stem cells (Review) S2: 47
review of literature 631 in peripheral blood progenitor cell transplantation (Introduction) $2: |
clonal evolution corticosteroids
and tumour heterogeneity (Review) 121 in granulosa cell tumour of the ovary (Clinical case) 521
clonal heterogeneity counseling
analysis of Hodgkin's disease (Review) S4: 35 of genetic testing (Special article) 891
clonality CPT-11
and tumour heterogeneity (Review) 121 dosage schedules 837
in B-cell lymphoma (Clinical case) 953 cromoglycate
of Hodgkin and Reed-Sternberg cells (Review) $4: 11 docetaxel rechallenge (Editorial) 104
clubbing current strategies
in a patient with metastatic carcinoma of the breast (Letter to the editor) in treatment of Hodgkin's disease (Review) S4: 109
756 cyclin D1
CMF identification of molecular alterators (Editorial) 222
as a treatment for patients with breast cancer (Short report) 409 involvement in hairy cell leukemia 251
combined with adjuvant prednisone 245 clinical significance of 695
effects of treatment in patients with breast cancer 245 cyclin-dependent kinase
effects on patterns of relapse 245 fundamental research (Commentary) 343
infusional (Short report) 409 cyclin-dependent kinase inhibitors
cognitive function fundamental research (Commentary) 343
effect of hypnotics discontinuation (Short report) 855 cyclins
colon cancer fundamental research (Commentary) 343
multifocal leukoencephalopathy (Short report) 412 cyclophosphamide
treatment with levamisole adjuvant therapy (Short report) 412 delayed emesis inducement 71
colony stimulating factors cytogenetics
treatment of patients with HIV-related non-Hodgkin's lymphomas (Arena) in Hodgkin's disease (Review) S4: 49
233 cytokines
colorectal cancer haemopoietic stem cells (Review) S2: 47
magnetic resonance spectroscopy 47 in peripheral blood progenitor cell transplantation (Introduction) $2: |
phase I study (Short report) 317 production in adult mice (Review) S2: 15
prolonged continuous hepatic artery infusion with interleukin-2 (Short production in patients with AML 397
report) 317 purging of peripheral blood progenitor cells (Review) $2: 11
TCNU (Letter to the editor) 211 treatment with interleukin-10 397
treatment with bFGF and VEGF 843 cytolitic T-lymphocytes
treatment with 5-fluorouracil 41, (Editorial) 531 perspectives for peptide-based vaccines (Review) 339
treatment with 5-fluorouracil plus a-interferon 575 recognition of tumour-associated antigens (Review) 339
unresectable liver metastases (Short report) 317
colorectal cancer (advanced) D
phase II trial 581 DAM486IL-2
randomised trial (Short report) 961 clinical use in Hodgkin's disease (Review) S4: 135
1092
delayed emesis as a treatment for patients with Hodgkin’s disease 151
caused by emetogenic chemotherapy 71
cisplatin-induced 945 E
oral dexamethasone in prophylaxis 71 early breast cancer
delayed nausea treatment with adjuvant chemotherapy 239
cisplatin-induced 945 treatment with tamoxifen 239
detoxification early stages
role of the LRP protein 625 of Hodgkin's disease (Review) S4: 79, 85, 91
dexamethasone EBV-specific immunity
compared to placebos and ondansetron 945 by EBV-induced modulation of cytokine expression pattern of HRS cells
for control of cisplatin-induced delayed emesis 945 (Review) S4: 11
prevention of hypersensitive reactions to paclitaxel (Letter to the editor) 8-chloroadenosine 3’, 5’-monophosphate (8-Cl-cAMP)
978 metabolism 291
emetogenic chemotherapy 71 pharmacokinetics 291
developmental therapeutics treatment for patients with breast cancer 291
in the treatment of patients with germ-cell tumours (Review) 997 tumour disposition 291
diarrhoea elderly patients
comparing drugs for the prevention of 587 age specific differences 677
disseminating disease diagnostics and treatment 677
expression of tyrosinase 297 effects of granulocyte colony-stimulating factor administration (Short
reverse transcriptase-polymerase chain reaction 297 report) 966
through perpiheral blood 297 treatment with a pirarubicin-combination chemotherapy regimen (Short
DNA primase report) 966
in cancer therapy (Review) 659 emesis
DNA topoisomerase I inhibitor cisplatin induced 277
in CPT-11 837 comparing drugs for the prevention of nausea 587
docetaxel in patients undergoing fractionated radiotherapy 587
efficacy and safety as a treatment for patients with advanced breast cancer optimum therapy 277
165 end results
rechallenge with cromoglycate (Editorial) 104 of the treatment of patients with Hodgkin’s disease (Special article) 555
dosage schedules endocrine pancreatic tumours
of CPT-11 837 treatment with chemotherapy (Review) 453
dose endocrine therapy
phase I trials (Commentary) 567 as a treatment of patients with breast cancer (Short report) 99
dose escalation endometrial cancer
current Clinical trials in Hodgkin’s disease (Review) S4: 109 treatment with paclitaxel (Short report) 861
of high-dose CDE with G-CSF for poor-risk non-Hodgkin’s lyphoma endothelium
1037 influence of 5-fluorouracil and methotrexate 731
phase I trials (Commentary) 567 epidemiology
dose-finding importance (Editorial) 439
study in chemotherapy 505 of cancer 497
of tropisetron 505 of EBV and Hodgkin’s lymphoma (Review) S4: 5
dose intensity epidoxorubicin
in chemotherapy for patients with adult solid tumours (Review) S2: 23 distribution in mice (Rapid publication) 801
in chemotherapy for patients with breast cancer 35, (Review) S2: 31 epithelial neoplasms
in primary chemotherapy for patients with ovarian carcinoma 705 the role of chemotherapy (Review) S2: 23
in therapy for patients with colorectal cancer 41 Epstein-Barr virus (EBV)
peripheral blood progenitor cells (Review) S2: 11 after solid organ transplantation 265
dose-limiting toxicity and Hodgkin’s disease 265, (Symposium article) S4: 45
phase I trials (Commentary) 567 epidemiology and Hodgkin’s lymphoma (Review) S4: 5
dose-response its role in the pathogenesis of Hodgkin's disease (Review) S4: 11
in patients with breast cancer (Review) $2: 31 Erwinia chrysanthemi
relationship in patients with advanced Hodgkin’s disease (Review) S4: 95 exposures to children with acute lymphoblastic leukemia 725
doxorubicin esophagogastric junction area
in advanced breast cancer 687 advanced adenocarcinoma (Short report) 533
drug therapy treatment with 5-FU and folinic acid (Short report) 533
and hematopoietic rescue 151 esophagus
advanced adenocarcinoma (Short report) 533
1093
treatment with 5-FU and folinic acid (Short report) 533 in combination therapy in metastatic carcinoid and malignant endocrine
estrogen receptors pancreatic tumours (Short report) 208
in breast cancer cells 391 in combination with leucovorin 581
estrogenic recruitment infusional (Short report) 55, 409, 581, (Editorial) 771, 807
in metastatic breast cancer 487 measurement of plasma 47
ethics neurotoxicity (Letter to the editor) 213
of euthanasia 907 phase I/II study 55, 581
European perspective radiotherapy 511
on clinical benefits (Editorial) 333 5-fluorouracil infusion
euthanasia as a treatment for patients with advanced breast cancer 807
ethics of 907 5-HT3 receptor antagonist
physician-assisted (Editorial) 879 compared with placebos and dexamethasone 945
versus palliative care (Letter to the editor) 645, (Editorial) 879 for the control of cisplatin-induced delayed emesis 945
ex vivo expansion floxuridine
of stem cells in mice (Review) S2: 15 in combination with recombinant a2b-interferon 601
ex vivo purging treatment of patients with metastatic renal cell carcinoma 601
of peripheral blood progenitor cells (Review) S2: 11 fludarabine
extradonal lymphomas as a treatment for patients with LCC 373
state-of-the-art (Commentary) 787 in therapy of low-grade follicular lymphoma (Review) S6: 41
treatment (Commentary) 787 long term survival 373
evaluation criteria folinic acid
for response rates in advanced colorectal cancer (Arena) 901 as a treatment for patients with advanced adenocarcinoma of the esopha-
gus (Short report) 533
F cancer chemotherapy 283
FA administration 5-fluorouracil association 283
neurotoxicity (Letter to the editor) 213 in combination with 5-FU (Short report) 533
fadrozole phase I/II study 55
versus tamoxifen in patients with advanced breast cancer 471 follicular lymphoma
versus tamoxifen in patients with metastatic breast cancer 465 histological transformation (Clinical case) 849
fallopiantube carcinoma stage lo 713
survival analysis 271 2-CDA therapy (Rapid publication) 793
fibrinogen wait-and-see policy 713
interaction between HRT and tamoxifen 671 follicular small cleaved cell lymphoma
FICTION treatment with combined chemotherapy-radiotherapy 157
and the monoclonality of Hodgkin and Reed-Sternberg cells (Review) S4: fractionated radiotherapy
49 prevention of nausea and vomiting in patients 586
financial costs future perspectives
of intravenous infusion with 5-fluorouracil 807 for the treatment of Hodgkin's disease (Symposium article) $4: 127
FISH
molecular cytogenetics in Hodgkin’s disease (Review) S4: 49 G
fixed effects G-CSF
in childhood leukemia clinical research (Arena) 1009 in elderly patients (Short report) 966
5-fluorouracil in patients with advanced non-small lung cancer and malignant melanoma
and methotrexate on vascular endothelium 731 (Short report) 1080
as a treatment for patients with advanced colorectal cancer 581 in patients with HIV-related non-Hodgkin's lymphoma 1029
as a treatment for patients with advanced pancreatic adenocarcinoma 173 in patients with poor-risk non-Hodgkin's lyphoma 1037
as a treatment for patients with biliary tract cancer (Letter to the editor) gemcitabine
Oat as a treatment for patients with pancreatic cancer (Editorial) 335, (Rapid
as a treatment for patients with breast cancer (Short report) 409, (Editorial) publication) 347
771 phase II trial (Rapid publication) 347
as a treatment for patients with metastatic colorectal carcinoma 575 gene rearrangement
biologically modulated by folinic acid (Letter to the editor) 644 in the peripheral blood of patients with diffuse large B-cell lymphomas
comparison of results to tissue dry levels with or without interferon a 1023
(Short report) 533 gene therapy
folinic acid association 283 as a new therapy for cancer (Special article) 449
in advanced adenocarcinoma (Short report) 533 expanding cord blood after allogeneic transplantation (Review) S2: 47
in cancer chemotherapy 283 for patients with metastatic renal cell cancer (Review) 887
in colorectal cancer 41, (Editorial) 551, 581 in peripheral blood progenitor cell transplantation (Introduction) $2: |
1094
the challenge for the future (Review) S2: 53 pretransplant malignancy in candidates and posttransplant malignancy in
gene transfer recipients 1059
in mice and man (Review) S2: 53 Helicobacter pylori
genetic testing association with MALT lymphoma (Commentary) 787
prevention of hereditary nonpolyposis colorectal cancer (Special article) hematological recovery
891 prognostic factors for autograft patients 719
germ cell neoplasms heparan sulfate
the role of chemotherapy (Review) $2: 23 as a treatment for patients with advanced malignancies 939
germ-cell tumours heparinoid
carboplatin in combination chemotherapy (Editorial) 989 pentosan 939
high-dose chemotherapy (Review) 997 hepatic artery infusion
GM-CSF in liver metastases of colorectal cancer (Short report) 317
in patients with AML 397 with interleukin-2 (Short report) 317
in patients with metastatic breast cancer 35 hereditary colon cancer
treatment with interleukin-10 397 prevention by genetic testing (Special article) 891
gonadal dysfunction after chemotherapy high-dose chemotherapy
late effects in childhood Hodgkin’s lymphoma (Review) S4: 67 for Hodgkin’s lymphoma (Symposium article) $4: 131
graft versus host disease for patients with poor-risk non-Hodgkin’s lyphoma 1037
allogeneic transplantation of peripheral blood progenitor cells (Review) in germ-cell tumours (Review) 997
$2: 41 high-dose single agent chemotherapy
in chronic myelogenous leukaemia (Review) S2: 19 in Hodgkin’s disease (Review) S4: 109
granisetron high-dose VP-16
in emetogenic chemotherapy 71 in patients with bone marrow transplantation 83
granulocytic sarcoma high performance liquid chromatography
isolated (Letter to the editor) 424 measurement of plasma 5-FU 47
granulocyte colony stimulating factor treatment of patients with colorectal cancer 47
in allogeneic transplantation of peripheral blood progenitor cells (Review) histopathology
$2: 41 of lymphocyte predominant Hodgkin’s disease (Symposium article) S4:
granulocyte growth factors 61
in adult solid tumours (Review) $2: 23 historical control studies
in haemopoietic stem cells (Review) S2: 5 compared with randomized trials 355
in progenitors (Introduction) S2: 1 of patients with esophageal cacrcinoma 355
in stem cells of adult mice (Review) S2: 15 HIV
granulosa cell tumour hematopoeitic colony-stimulating factors (Arena) 233
of the ovary (Clinical case) 521 related with non-Hodgkin’s lymphoma’s (Arena) 233
growth factors Hodgkin’s disease
after treatment with pentosan 939 analysis of tumor cells (Symposium article) $4: 45
autologous hematopoietic rescue 151
H brief chemotherapy and adjuvant radiotherapy (Review) S4: 105
haemoptysis clinical trials (Symposium article) $4: 127
in a patient with metastatic carcinoma of the breast (Letter to the editor) complications by second cancers (Clinical case) 405
756 current clinical trials (Review) S4: 109
haematopoiesis current strategies (Review) S4: 91
transplantation of peripheral blood progenitor cells (Review) S2: 41 cytogenetics and molecular vytogenetics (Review) S4: 49
haematopoietic stem cells development of immunotoxins for potential use (Review) S4: 135
cord blood as an alternative source (Review) S2: 47 early high dose chemotherapy (Symposium article) $4: 131
repopulating ability in mice (Review) S2: 15 early stage (Editorial) 115, (Review) 85, 91
study of cells in patients (Review) S2: 5 evidence of the Epstein-Barr virus 265
haematopoietic stem cell transplantation following solid organ transplantation 265
and drug therapy 151 Ig rearrangements in isolated Reed-Sternberg cells (Review) S4: 31
in Hodgkin’s disease patients 151 increased risks in females 257
hairy cell leukemia (HCL) interactive signals in the pathobiology (Review) S4: 19
involvement of the CCND1 gene 251 late complications (Review) S4: 115
head and neck cancer long-term results of radiotherapy 145
treatment with chemotherapy 15 management of early stage (Review) S4: 79
head and neck neoplasms meningeal localization in a patient (Clinical case) 1071
re-irradiation with concomitant chemotherapy 913 occurrence of cardiopulmonary sequelae 257
heart transplantation patients with an incomplete response to front-line therapy 1043
preliminary experience with paclitaxel (Short report) 1083 immunotherapy
present and future strategies of treatment in childhood (Review) $4: 73 of Hodgkin's disease (Review) S4: 143
rationale for dose escalation of first line conventional chemotherapy of metastatic renal cell cancer (Review) 887
(Review) S4: 95 monitoring of cancer vaccins (Commentary) 667
role of Epstein-Barr virus in the pathogenesis (Review) S4: 11 immunotoxin
role of radiation therapy and/or chemotherapy (Review) S4: 79 development for potential clinical use in Hodgkin's disease (Review) S4
role of radiation therapy in advanced disease (Review) S4: 99 135
single cell analysis of Hodgkin/Reed-Sternberg cells (Review) S4: 27, 41 in vitro expansion
single cell PCR for the analysis (Review) S4: 35 of haemopoietic stem cells (Review) S2: 47
treatment (Special article) 555 in vivo purging
treatment with bispecific antibodies (Review) S4: 143 of peripheral blood progenitor cells (Review) S2: 11
treatment with high-dose chemotherapy 151 incidence
Hodgkin's lymphoma and mortality 497
epidemiology (Review) S4: 5 Indiana University classification
overview of the Third International Symposium (Introduction) S4: 1 randomized trial for patients with good-risk metastatic non-seminomatous
hormonal replacement therapy germ cell tumours 1015
as a treatment for patients with a breast cancer history (Editorial) 655 indoloquinone EO9
effect on serum cholesterol, bone mineral density and coagulation factors in non-small-cell lung cancer (Short report) 529
671 induction failure
interaction with tamoxifen 671 in patients with lyphoma 1043
HUMARA gene assay inflammatory disease
in single cell analysis of H/RS cells (Review) S4: 41 dose-response effect (Review) $2: 31
hypnotics infusional
discontinuation in terminal cancer patients (Short report) 855 CMF (Short report) 409
inter-abdominal abscess
I complications for chemotherapy (Letter to the editor) 536
ifosfamide interaction
as a treatment for patients with advanced ovarian cancer (Short report) between paclitaxel and EpiDx (Rapid publication) 801
419 interferon
as a treatment for patients with malignant melanoma (Short report) 1080 as a treatment for patients with colorectal cancer patients 47
as a treatment for patients with non-small-cell lung cancer (Short report) as a treatment for patients with metastatic renal cell carcinoma 601
311, 314, 747, (Short report) 637, (Short report) 1080 in combination with floxuridine 601
in combination with methylene-blue (Letter to the editor) 643 interferon-a
in salvage therapy (Short report) 419 as a treatment for patients with chronic myelogenous leukaemia (Review)
phase I study (Short report) 311, 314 $2: 19
phase II study (Short report) 637, (Short report) 1080 as a treatment for patients with metastatic melanoma 827
oral versus intravenous (Short report) 637 in combination with biotherapy 827
Ig gene rearrangements intergroup trials
in Hodgkin/Reed-Sternberg cells (Review) S4: 27 prospective meta-analysis strategy (Arena) 1005
imaging procedures interleukin-2
in Hodgkin’s disease (Review) S4: 55 as a treatment for out-patients with metastatic renal cell carcinoma (Short
immunogenotype report) 525
in lymphocytic leukemia (Clinical case) 953 as a treatment for patients with colorectal cancer (Short report) 317
immunoglobulin gene rearrangement as a treatment for patients with metastatic melanoma 827
by PCR in single cell analysis of H/RS cells $4: 41 prolonged continuous hepatic artery infusion (Short report) 317
immunoglobulin heavy chain rearrangements phase I study (Short report) 317
in HRS cells (Review) S4: 35 peripheral nerve entrapment (Letter to the editor) 535
immunoglobulin rearrangement interleukin1-0
in isolated Reed-Sternberg cells (Review) S4: 31 for patients with AML 397
yhistochemistry inhibition of cytokine production 397
detection of MRP expression 75 interleukins
in hairy cell leukemia 251 as a treatment for patients with metastatic renal cell cancer (Review) 887
involvement of theC CND1 gene 251 intermediate- to high-grade non-Hodgkin's lymphomas
involvement of the LRP gene 625 combined modality treatment 919
immunophenotype investigational agents
in lymphocytic leukemia (Clinical case) 953 in patients with refractory malignancies 491
immunoscintigraphy irinotecan
new diagnostic procedure in Hodgkin's disease (Review) S4: 55 dosage schedules 837
1096
islet cell lung resistance-related protein (LRP)
combination therapy with interferon-a-2a and 5-FU (Short report) 208 expression in human lung cancer 625
isolated granulocytic sarcoma role in drug resistance 625
of the breast (Letter to the editor) 424 lymphoma
clonal analysis (Clinical case) 953
L evolution into lymphocytic leukemia (Clinical case) 953
L-asparaginase treatment with a pirarubicin-combination chemotherapy regimen (Short
exposure to Erwinia 725 report) 966
L-asparagine depletion treatment with paclitaxel (Short report) 1083
in children with acute lymphoblastic leukemia 725 lymphopoiesis
laboratory reconstruction after allogeneic transplantation of peripheral blood progen-
research of ovarian cancer 9 itor cells (Review) S2: 41
large cell lymphoma lymphocyte predominance Hodgkin’s disease
clinical significance of bcl-2 (MBR)/JH rearrangement in the peripheral a workshop report (Symposium article) S4: 61
blood 1023
late complications M
after Hodgkin’s disease (Review) S4: 115 magnetic resonance spectroscopy
late effects of chemotherapy of colorectal cancer 47
in childhood Hodgkin’s lymphoma (Review) S4: 67 malignancy
leptomeningitis in recipients of cardiac transplantation 1059
carcinomatous meningitis (Review) 773 malignant glioma
letrozole phase II study (Short report) 205
as a treatment for patients with breast cancer (Short report) 99 MALT lymphoma
leucovorin combined modality therapy (Letter to the editor) 211
as a treatment for patients with advanced colorectal cancer 581 Helicobacter pylori (Commentary) 787
as a treatment for patients with advanced pancreatic adenocarcinoma 173 purine analogs (Review) S6: 21
in combination with 5-FU 581 state-of-the-art (Commentary) 787
leukaemia MALToma
complicating Hodgkin’s disease (Clinical case) 405 new classification (Review) S6: 3
levamisole management
role in treatment of patients with colorectal cancer 41 of patients with tumour lysis syndrome (Clinical case) 631
ligands mantle cell lymphoma (MCL)
TNF superfamilies in the pathobiology of Hodgkin’s disease (Review) S4: classification and therapeutic implications (Review) S6: 35
19 treatment with combined modality therapy (Letter to the editor) 211
limited stages marginal-zone lymphomas
causing complications 713 purine analogs (Review) S6: 21
LMP1 marrow repopulation
pathogenesis of Hodgkin’s disease (Review) S4: 11 in mice (Review) S2: 15
localized maspin
stage NHL 919 reverse-transcriptase polymerase chain reaction of 619
locally advanced breast cancer role in breast cancer 619
efficacy and safety of docetaxel 165 matrix attachment regions
low-dose continuous in cancer therapy (Review) 659
intravenous infusion of 5-fluorouracil 807 melanoma
low-grade follicular lymphoma identification in peripheral blood 297
purine nucleoside therapy (Review) S6: 41 treatment with biochemotherapy 827
lung cancer melphalan
carcinomatous meningitis (Review) 773 as a treatment for patients with ovarian cancer 65
expression of the LRP protein 625 meningeal lymphoma
non-small-cell (Editorial) 119, (Short report) 311, 314 in patients with Hodgkin’s disease (Clinical case) 1071
phase I study (Short report) 311, 314 meta-analysis
radiotherapy preceded by high-dose chemotherapy versus high-dose radio- strategy in childhood leukemia clinical research (Arena) 1009
therapy 139 metabolism
randomized phase II trials (Letter to the editor) 755 in patients with breast cancer 291
role of surgery in small-cell (Clinical case) 303 of 8-chloroadenosine 3’ ,5’-monophosphate 291
treatment with chemotherapy (Short report) 311, 314 metastasis
lung neoplasms treatment with neoadjuvant chemotherapy (Short report) 864
the role of chemotherapy (Review) S2: 23 metastatic breast cancer